ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)
NCT05347992 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 423
Last updated 2025-01-07
Summary
To explore the potential for use of DxTerity's AIP IFN-1 test as personalized guided care and monitoring module in patients with Systemic lupus erythematosus(SLE) using consented patient health information
Conditions
Sponsors & Collaborators
-
DxTerity Diagnostics
lead INDUSTRY
Principal Investigators
-
Robert Terbrueggen, PhD · DxTerity Diagnostics
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-03
- Primary Completion
- 2023-05-25
- Completion
- 2023-08-17
Countries
- United States
Study Locations
More Related Trials
-
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
NCT06804057 ·Status: RECRUITING
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
NCT02034344 ·Status: COMPLETED
-
Rituximab Objective Outcome Measures Trial in SLE
NCT03054259 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Telitacicept in Early SLE
NCT05899907 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01196091 ·Status: COMPLETED ·Phase: PHASE3
-
Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients
NCT04266860 ·Status: COMPLETED ·Phase: NA
-
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
NCT05203419 ·Status: TERMINATED ·Phase: PHASE1
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
T Regulatory Cells IN LUPUS NEPHRITIS
NCT06428539 ·Status: NOT_YET_RECRUITING
-
Autologous Polyclonal Tregs for Lupus
NCT02428309 ·Status: TERMINATED ·Phase: PHASE1
-
On Open-Label Study in Participants With Systemic Lupus Erythematosus
NCT01488708 ·Status: TERMINATED ·Phase: PHASE3
-
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus
NCT00008749 ·Status: UNKNOWN
-
Molecular Diagnosis of Systemic Autoinflammatory Diseases
NCT05364294 ·Status: RECRUITING
-
Lymphocyte Sub-populations and Auto Immune Diseases
NCT03901664 ·Status: COMPLETED
-
Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus
NCT05791799 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)
NCT05426902 ·Status: COMPLETED ·Phase: NA
-
Long-Term Outcomes in SLE at Peking University People's Hospital
NCT07005479 ·Status: RECRUITING
-
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
NCT07314567 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)
NCT00750971 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)
NCT00299819 ·Status: COMPLETED ·Phase: PHASE1
-
IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage
NCT05045417 ·Status: UNKNOWN
-
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
NCT06710717 ·Status: RECRUITING ·Phase: PHASE1